Navigation Links
New Details Presented at the World Parkinson Congress on Neurologix's Successful Phase 2 Trial of Gene Therapy for Parkinson's Disease
Date:10/1/2010

Style" type="disc">
  • The Company is still in the development stage and has not generated any revenues. From inception through June 30, 2010, it incurred net losses and negative cash flows from operating activities of approximately $55.7 million and $41.6 million, respectively. Management believes that the Company will continue to incur net losses and cash flow deficiencies from operating activities for the foreseeable future. Because it may take years to develop, test and obtain regulatory approval for a gene-based therapy product before it can be sold, the Company likely will continue to incur significant losses for the foreseeable future. Accordingly, it may never be profitable and, if it does become profitable, it may be unable to sustain profitability.
  • At June 30, 2010, the Company had cash and cash equivalents of approximately $4.5 million. Based on its cash flow projections, the Company will need additional financing to carry out its planned business activity and to complete its plan of operations through December 31, 2010. At the Company's present level of activities, the Company's cash and cash equivalents are believed, at this time, to be sufficient to fund its operations only into the fourth quarter of 2010. Accordingly, there is substantial doubt as to the Company's ability to continue as a going concern. The Company is currently seeking to raise funds, through public or private equity offerings, debt financings or corporate collaboration and licensing arrangements, sufficient to finance its ongoing operations. The Company does not know whether additional financing will be available when needed, or if available, will be on acceptable or favorable terms to it or its stockholders.
  • The Company will need to conduct future clinical trials for treatment of Parkinson's disease using the Company's NLX technology. If the trials prove unsuccessful, future operations and the potential for profitability will be materially adversel
    '/>"/>

  • SOURCE Neurologix, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related medicine technology :

    1. PulmoBioTech Announces Details of Its Regulatory Approval Experiments
    2. Pulmo BioTech Announces Details of the Methodology for its Phase I Human Trials
    3. Newly Published Article Details How PGS Techniques Directly Effect Successful Pregnancy Outcomes
    4. Kendle Announces Details Regarding Third Quarter 2009 Earnings Conference Call and Webcast
    5. Young Innovations, Inc. Provides Third Quarter Conference Call Details
    6. Cord Blood America Details Las Vegas Laboratory Progress in Analyst Interview
    7. Young Innovations, Inc. Provides 4th Quarter Conference Call Details
    8. Kendle Announces Details Regarding Second Quarter 2010 Earnings Conference Call and Webcast
    9. Young Innovations, Inc. Provides 2nd Quarter Conference Call Details
    10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
    11. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:3/3/2015)...  American Biosurgical, LLC ("ABI") ( www.americanbiosurgical.com ) ... engaged in the design, development and production of ... medical device companies has announced the acquisition of ... medical cable manufacturer based in North Carolina.  The ... the name MTI Medical Cables.  ...
    (Date:3/3/2015)... 2015  Web Industries, Inc., a leading provider ... Medical Device, Advanced Composites, Consumer Products, and Wire ... Medical Specialties Preferred Converter by 3M,s Medical Specialties ... to streamline their supply chains by using Web ... materials, intermediate converting services, and contract manufacturing and ...
    (Date:3/3/2015)... Registration is officially open for MEDTEC China South ... the Shenzhen Convention & Exhibition Center. The Shenzhen ... join the MEDTEC China family of events. MEDTEC China South, ... better serve the South China market ... important region for China,s medical device ...
    Breaking Medicine Technology:American Biosurgical Acquires MTI Corporation 2Web Industries Receives 3M Preferred Converter Status 2Pre-registration Open for 2015 MEDTEC China South 2Pre-registration Open for 2015 MEDTEC China South 3
    ... , VIENNA, Va., Dec. 1 CEL-SCI Corporation (NYSE Amex: ... of vaccines and therapeutics for the prevention and treatment of ... of an international Contract Research Organization (CRO) to run CEL-SCI,s ... neck cancer with the Company,s lead product candidate, Multikine®. ...
    ... , MT. LAUREL, N.J., Dec. 1 MedQuist ... clinical documentation services, today announced that the radiology search tool ... Radiology(TM), MedQuist,s real-time speech recognition system. The solution is being ... November 29 through December 2. , Radiologists ...
    Cached Medicine Technology:CEL-SCI Retains Global Contract Research Organization to Manage Upcoming Phase III Clinical Trial for Its Cancer Drug Multikine 2CEL-SCI Retains Global Contract Research Organization to Manage Upcoming Phase III Clinical Trial for Its Cancer Drug Multikine 3MedQuist Integrates Search Engine from Primordial with SpeechQ(TM) for Radiology 2
    (Date:3/4/2015)... 2015 Follow us on ... growth worldwide, supported by the numerous intraoperative, and ... and single incision surgery will continue to spur ... invasive surgery, driving its adoption among patients and ... site, lower blood loss, shorter hospital stays, faster ...
    (Date:3/4/2015)... (PRWEB) March 04, 2015 Bird B ... industrial and residential applications now offers its popular plastic ... The humane, highly efficient bird deterrent is ... match the color and décor of the building or ... colors—brick red, white, crystal clear, light grey, brown, black ...
    (Date:3/4/2015)... Mexia, Texas & Ennis, Texas (PRWEB) March 04, ... Ennis Regional Medical Center today announced that Alan ... of both hospitals, effective immediately. Daugherty has served ... Regional since October 2014. , “Alan has provided ... and has demonstrated exceptional abilities leading hospital strategy ...
    (Date:3/3/2015)... Anik Singal's Profit Academy ... ambitious online marketers has become the talk of ... media attention surrounding the course's general release has ... Hendricks, prompting her to review the program's content ... of the biggest keys to success with Internet ...
    (Date:3/3/2015)... Loma Linda University Health announced today, ... being, it will be offering new, healthier choices in ... Over the past year, a cross-section of Loma Linda ... criteria, listening to vendors, sampling their products, and ultimately ... , Most recently, a food fair was held during ...
    Breaking Medicine News(10 mins):Health News:Growing Demand for Less Invasive Procedures Drives Growth in the Endoscopy Systems Market, According to a New Report by Global Industry Analysts, Inc. 2Health News:Growing Demand for Less Invasive Procedures Drives Growth in the Endoscopy Systems Market, According to a New Report by Global Industry Analysts, Inc. 3Health News:Growing Demand for Less Invasive Procedures Drives Growth in the Endoscopy Systems Market, According to a New Report by Global Industry Analysts, Inc. 4Health News:Plastic Bird Spikes Now Come in 7 Colors to Blend in With Their Surroundings 2Health News:Alan Daugherty Named CEO of Parkview Regional Hospital and Ennis Regional Medical Center 2Health News:Alan Daugherty Named CEO of Parkview Regional Hospital and Ennis Regional Medical Center 3Health News:Anik Singal's Profit Academy - Review Of New IM Training Program Released 2Health News:Loma Linda University Health Rejuvenates Its Vending Machines with Healthier Selections 2
    ... from the University of Washington, Seattle, and colleagues, have ... Moderately elevated levels of insulin increase the levels ... in cerebrospinal fluid and these markers may contribute to ... healthy older adults ranging in age from 55 to ...
    ... Hyderabad has unraveled the mystery behind gene silencing, paving ... in human beings//. ,Two scientists - Manika Pal ... novel finding to fight a disease, which has remained ... silencing segments of the genes (heterochromatin), which are responsible ...
    ... is a complex decision and early detection of cancer will ... problems for others leading to unnecessary testing and treatment. Celebrities ... can be used for early detection of cancer// , ... in the Journal of the National Cancer Institute reported that ...
    ... University School of Medicine had said in a research finding ... that the disease called Rocky Mountain spotted fever may spread ... ,The research highlights the importance of the recent outbreak ... be traced back to ticks carried into to the state ...
    ... has been designed to help researchers track a tracer chemical, monamine ... enzyme has been found to play a crucial role in blood ... B. ,The study showed that levels of MAO B ... - were reduced by 40 to 50 percent compared to non-smokers. ...
    ... elderly people who exercise regularly and have a certain gene ... movements than the people who lack the gene expression. ... School of Medicine was published // in the latest issue ... climbing steps) is common and is strongly related to major ...
    Cached Medicine News:Health News:Influence of Celebrities on Breast Cancer Awareness 2Health News:Influence of Celebrities on Breast Cancer Awareness 3Health News:Influence of Celebrities on Breast Cancer Awareness 4Health News:Influence of Celebrities on Breast Cancer Awareness 5Health News:Spread Of Rocky Mountain Spotted Fever Is A Probability, Say Experts 2Health News:Gene Variation Associated With Better Mobility For Older Individuals 2
    ... Only 1-2% of circulating testosterone exists as ... 60%, is bound to SHBG with high ... bound to albumin. Both the albumin-bound and ... SHBG effectively inhibits testosterone action. Measurement of ...
    ... (T4) is the primary active hormone synthesized ... gland [1]. T4 is synthesized via a ... by the follicular cells, (ii) iodination of ... to formation of 3-monoiodotyrosine and 3,5-diiodotyrosine (MIT ...
    ... Human Insulin-like growth factor binding protein-3 (IGFBP-3) is ... in postnatal serum, as a component of the ... IGFBP-3, a molecule of IGF-I or IGF-II and ... the actions of the IGFs. The molar concentration ...
    ... (GH) is a monomeric protein produced and ... gland. GH is released from the pituitary ... under the regulatory control of hypothalamic somatostatin ... timing and frequency of GH release appears ...
    Medicine Products: